Galapagos wants to remain as stand-alone business
Galapagos [AMS: GLPG], the Dutch pharmaceutical business, wants to remain as a standalone business, CEO Onno van de Stolpe said on Dutch Business News Radio.
There has been speculation that US-based competitor Gilead [NASDAQ: GILD] could launch a takeover bid of the company, however Van de Stolpe said the firm is a good partner in Galapagos' innovation projects, but no takeover attempt is in the cards, the item added.
Regarding its previously standstill agreement with Gilead, Van de Stolpe would not comment on the question when that expires, but only noted it's still in place.